The clinical utility of array-CGH and targeted NGS in
idiopathic intellectual disabilities and developmental delays:
a case report of SCN2A p.Ala263Val variant

a 2017

The clinical utility of array-CGH and targeted NGS in idiopathic intellectual disabilities and developmental delays: a case report of SCN2A p.Ala263Val variant

WAYHELOVÁ, Markéta, Jan OPPELT, Denisa VESELÁ, Jan SMETANA, Filip PARDY et. al.

Základní údaje

Originální název

The clinical utility of array-CGH and targeted NGS in idiopathic intellectual disabilities and developmental delays: a case report of SCN2A p.Ala263Val variant

Autoři

WAYHELOVÁ, Markéta (203 Česká republika, domácí), Jan OPPELT (203 Česká republika, domácí), Denisa VESELÁ (203 Česká republika, domácí), Jan SMETANA (203 Česká republika, domácí), Filip PARDY (203 Česká republika, domácí), Hana FILKOVÁ (203 Česká republika, domácí), Dita MATUCHOVÁ (203 Česká republika, domácí), Jana ŠOUKALOVÁ (203 Česká republika, domácí), Renata GAILLYOVÁ (203 Česká republika, domácí) a Petr KUGLÍK (203 Česká republika, garant, domácí)

Vydání

The European Human Genetics Conference ESHG 2017, 2017

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

10603 Genetics and heredity

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.636

Kód RIV

RIV/00216224:14310/17:00114994

Organizační jednotka

Přírodovědecká fakulta

ISSN

UT WoS

000489312603038

Klíčová slova anglicky

neurodevelopmental disorders; NGS; SCN2A

Změněno: 13. 5. 2021 18:14, Mgr. Markéta Wayhelová, Ph.D.

Anotace

V originále

Introduction: Next-generation sequencing (NGS) techniques have become a powerful tool for the identification of the genetic causes of the heterogeneous conditions such as intellectual disabilities, multiple congenital anomalies and autism spectrum disorders. Material and methods: We present our first experience with targeted NGS approach using commercially available design SureSelect Inherited Disease (Agilent Technologies) containing more than 2700 genes known to cause inherited disorders. We report on a case of 9-year-old boy with a diagnosis of severe intellectual disability related to early myoclonic encephalopathy. This patient was examined according to our investigatory algorithm, from G-banding karyotype (46,XY) to array-CGH on oligonucleotide DNA microarrays (Agilent Technologies) followed by confirmative targeted quantitative PCR and FISH. Results: We detected a de novo copy-number gain of 18q21.23 (539 kb) classified as probably benign. Consequently this patient was included in our pilot study using targeted NGS with pre-designed gene panel SureSelect Inherited disease and Illumina MiSeq. We detected de novo heterozygous missense genetic variant in SCN2A gene, resulting in the amino acid residue change from alanine to valine at position 263 (p.Ala263Val). This variant had been previously described as definitely pathogenic in patients with Otahara syndrome. Conclusions: This case has proved the usefulness and effectivity of our molecular diagnostics algorithm enhanced by NGS approaches leading to higher diagnostic yield of heterogeneous genetic conditions. This study was supported by Ministry of Health, Czech Republic [[unable to display character: –]] conceptual development of research organization (FNBr, 65269705).

Návaznosti

MUNI/A/0877/2016, interní kód MU

Název: Podpora výzkumné činnosti studentů molekulární biologie a genetiky 5 (Akronym: MBG5)

Investor: Masarykova univerzita, Podpora výzkumné činnosti studentů molekulární biologie a genetiky 5, DO R. 2020_Kategorie A - Specifický výzkum - Studentské výzkumné projekty

Citovat

WAYHELOVÁ, Markéta, Jan OPPELT, Denisa VESELÁ, Jan SMETANA, Filip PARDY, Hana FILKOVÁ, Dita MATUCHOVÁ, Jana ŠOUKALOVÁ, Renata GAILLYOVÁ a Petr KUGLÍK. The clinical utility of array-CGH and targeted NGS in idiopathic intellectual disabilities and developmental delays: a case report of SCN2A p.Ala263Val variant. In The European Human Genetics Conference ESHG 2017. 2017. ISSN 1018-4813.

@proceedings{1407163,
   author = {Wayhelová, Markéta and Oppelt, Jan and Veselá, Denisa and Smetana, Jan and Pardy, Filip and Filková, Hana and Matuchová, Dita and Šoukalová, Jana and Gaillyová, Renata and Kuglík, Petr},
   booktitle = {The European Human Genetics Conference ESHG 2017},
   keywords = {neurodevelopmental disorders; NGS; SCN2A},
   language = {eng},
   title = {The clinical utility of array-CGH and targeted NGS in idiopathic intellectual disabilities and developmental delays: a case report of SCN2A p.Ala263Val variant},
   year = {2017}
}

TY  - CONF
ID  - 1407163
AU  - Wayhelová, Markéta - Oppelt, Jan - Veselá, Denisa - Smetana, Jan - Pardy, Filip - Filková, Hana - Matuchová, Dita - Šoukalová, Jana - Gaillyová, Renata - Kuglík, Petr
PY  - 2017
TI  - The clinical utility of array-CGH and targeted NGS in idiopathic intellectual disabilities and developmental delays: a case report of SCN2A p.Ala263Val variant
KW  - neurodevelopmental disorders
KW  - NGS
KW  - SCN2A
N2  - Introduction: Next-generation sequencing (NGS) techniques have become a powerful tool for the identification of the genetic causes of the heterogeneous conditions such as intellectual disabilities, multiple congenital anomalies and autism spectrum disorders. Material and methods: We present our first experience with targeted NGS approach using commercially available design SureSelect Inherited Disease (Agilent Technologies) containing more than 2700 genes known to cause inherited disorders. We report on a case of 9-year-old boy with a diagnosis of severe intellectual disability related to early myoclonic encephalopathy. This patient was examined according to our investigatory algorithm, from G-banding karyotype (46,XY) to array-CGH on oligonucleotide DNA microarrays (Agilent Technologies) followed by confirmative targeted quantitative PCR and FISH. Results: We detected a de novo copy-number gain of 18q21.23 (539 kb) classified as probably benign. Consequently this patient was included in our pilot study using targeted NGS with pre-designed gene panel SureSelect Inherited disease and Illumina MiSeq. We detected de novo heterozygous missense genetic variant in SCN2A gene, resulting in the amino acid residue change from alanine to valine at position 263 (p.Ala263Val). This variant had been previously described as definitely pathogenic in patients with Otahara syndrome. Conclusions: This case has proved the usefulness and effectivity of our molecular diagnostics algorithm enhanced by NGS approaches leading to higher diagnostic yield of heterogeneous genetic conditions. This study was supported by Ministry of Health, Czech Republic [[unable to display character: –]] conceptual development of research organization (FNBr, 65269705).
ER  -

WAYHELOVÁ, Markéta, Jan OPPELT, Denisa VESELÁ, Jan SMETANA, Filip PARDY, Hana FILKOVÁ, Dita MATUCHOVÁ, Jana ŠOUKALOVÁ, Renata GAILLYOVÁ a Petr KUGLÍK. The clinical utility of array-CGH and targeted NGS in idiopathic intellectual disabilities and developmental delays: a case report of SCN2A p.Ala263Val variant. In \textit{The European Human Genetics Conference ESHG 2017}. 2017. ISSN~1018-4813.

Podrobný výpis o publikaci